10x Genomics price to sales ratio TXG

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 15.1×
7-year median: 9.8×
Against its 7-year history: 67th; percentile: 0 is its lowest day, 100 its highest
7-year range: 1.5× to 80.9×
Peer median: 6.4×

10x Genomics' price to sales ratio is 15.1× as of Oct 23, 2026.

That is above its 7-year median of 9.8×, higher than on 67% of days in the last 7 years.

Over that time it ranged from 1.5× in Apr 2025 to 80.9× in Feb 2021.

The median for 10 diagnostics and research stocks of a similar size is 6.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.1×	3.3×	19.7×
2025	3.3×	1.5×	3.7×
2024	2.8×	2.6×	10.3×
2023	11.2×	7.1×	13.6×
2022	8.3×	5.9×	31.1×
2021	36.2×	33.6×	80.9×
2020	58.2×	21.9×	65.4×

Against its peers

Companies in Medical - Diagnostics & Research nearest 10x Genomics' size, closest first, today.

Company	Price to sales ratio
TXG10x Genomics	15.1×
CAICaris Life Sciences	9.1×
BIOBio-Rad Laboratories	3.8×
LNTHLantheus	4.2×
BLLNBillionToOne	12.8×
RVTYRevvity	6.1×
MEDPMedpace	6.7×
VCYTVeracyte	6.9×
CDNACareDx	7.8×
LHLabcorp	1.9×
DGXQuest Diagnostics	2.3×
Peer median	6.4×

Where 10x Genomics ranks

#52of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on 10x Genomics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.